Info

Elusys Therapeutics is a privately-held biopharmaceutical company focused on the development of antibody-based therapies for the treatment of infectious disease. The Company has pioneered the development of a rapid injection, therapeutic antibody, AnthimÔ, for the treatment of anthrax infection following a biowarfare attack. Anthim has completed a phase I safety study and is a leading candidate for purchase by the US government. Elusys' Heteropolymer (HP) Antibody technology targeting complement receptors has demonstrated a unique ability to clear and destroy pathogens and provides a platform to develop a broad pipeline of novel drug candidates targeted against bacterial, viral and fungal infections. ETI-211, a preclinical candidate for the treatment of antibiotic resistant Staphylococcus aureus (S. aureus) infections, has shown significant efficacy in animal studies and is being rapidly developed for entry into the clinic.